M.J.A. de JongeL. van DoornT. IsoeK. HayashiS. HussainL. EkmanH. BurgerJ. VerweijElsevier LtdEuropean Journal of Cancer SupplementsEskens FA, Planting A, Van Doorn L et al (2006) An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular ...